会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • 인간 에리스로포이에틴과 변형 에리스로포이에틴을 모두인식하는 모노클로날 항체 및 그를 생산하는 융합세포주
    • 单克隆抗体识别人类ERYTHROPOIETIN(EPO)和改良的ERYTHROPOIETIN和生产其的杂交细胞系
    • KR1020040046419A
    • 2004-06-05
    • KR1020020074347
    • 2002-11-27
    • 씨제이 주식회사
    • 김기완하병집오명석유창훈이동억정종상박지숙박형기안지원
    • C12N5/22
    • C12N5/163C07K16/22C07K2317/14C07K2317/31
    • PURPOSE: A monoclonal antibody recognizing both human erythropoietin(EPO) and modified erythropoietin and a hybridoma cell line producing the same are provided, thereby effectively purifying EPO and modified EPO using chromatography. CONSTITUTION: The hybridoma cell KCLRF-BP-00071 produces the monoclonal antibody recognizing both human erythropoietin(EPO) and modified erythropoietin. The method for preparing the hybridoma cell KCLRF-BP-00071 producing the monoclonal antibody recognizing both human erythropoietin(EPO) and modified erythropoietin comprises the steps of: immunizing a mouse with human EPO to obtain human EPO antibody, fusing the human EPO antibody with NS-O, and culturing the fused cells on wells to obtain hybridoma cells producing monoclonal human EPO antibody; adding first clones into the hybridoma cells and culturing them to obtain hybridoma cells producing monoclonal human EPO antibody; and selecting hybridoma cells producing monoclonal human EPO antibody recognizing both human erythropoietin(EPO) and modified erythropoietin.
    • 目的:提供识别人促红细胞生成素(EPO)和修饰的促红细胞生成素的单克隆抗体和产生该促红细胞生成素的杂交瘤细胞系,从而有效地纯化EPO和使用色谱法的改性EPO。 构成:杂交瘤细胞KCLRF-BP-00071产生识别人促红细胞生成素(EPO)和修饰的红细胞生成素的单克隆抗体。 制备识别人促红细胞生成素(EPO)和修饰促红细胞生成素的单克隆抗体的杂交瘤细胞KCLRF-BP-00071的方法包括以下步骤:用人EPO免疫小鼠以获得人EPO抗体,将人EPO抗体与NS融合 -O,并在孔上培养融合的细胞以获得产生单克隆人EPO抗体的杂交瘤细胞; 将第一个克隆加入到杂交瘤细胞中并培养它们以获得产生单克隆人EPO抗体的杂交瘤细胞; 并选择产生识别人促红细胞生成素(EPO)和修饰的红细胞生成素的单克隆人EPO抗体的杂交瘤细胞。
    • 8. 发明公开
    • 당쇄화된 인간 과립구 형성인자
    • 糖蛋白人造粒刺激因子(G-CSF)ISOFORM
    • KR1020040020816A
    • 2004-03-09
    • KR1020030060430
    • 2003-08-29
    • 씨제이 주식회사
    • 이은정김현석정종상김기완김연향이현수고형곤오명석
    • C07K14/47
    • C07K14/535A61K38/00
    • PURPOSE: A glycosylated human granulocyte colony stimulating factor(G-CSF) isoform is provided. The glycosylated hG-CSF isoform has improved stability in the human body, therefore it reduces dose and dosage frequency thereof when clinically applied. CONSTITUTION: A glycosylated human granulocyte colony stimulating factor(G-CSF) isoform is prepared by forming one or more sequences of Asn-X-Ser/Thr(N-X-S/T) on the amino acid residues: -T1-P10 (T1-P-L-G-P-A-S-S-L-P10), -Y39-L71 (Y39-K-L-C-H-P-E-E-L-V- L-L-G-H-S-L-G-I-P-W-A- P-L-S-S-C-P-S-Q-A-L-Q-L71); -L92-L99 (L92-E-G-I-S-P-E-L99); and -G125-S142 (G125-M-A-P-A-L-Q-P-T- Q-G-A-M-P-A-F-A-S142), and followed by glycosylation, wherein and glycine at amino acid position 51 is substituted by asparagine, glycine at amino acid position 94 is substituted by asparagine, threonine and glycine at amino acid position 133 and 135 are substituted by asparagine and serine, respectively, or all of them are modified.
    • 目的:提供糖基化的人粒细胞集落刺激因子(G-CSF)同种型。 糖基化的hG-CSF同种型在人体中具有改善的稳定性,因此在临床应用时降低其剂量和剂量频率。 构成:通过在氨基酸残基-T1-P10(T1-PLGPASSL)上形成一个或多个Asn-X-Ser / Thr(NXS / T)序列来制备糖基化的人粒细胞集落刺激因子(G-CSF)同种型 -P10),-Y39-L71(Y39-KLCHPEELV-LLGHSLGIPWA-PLSSCPSQALQ-L71); -L92-L99(L92-E-G-I-S-P-E-L99); 和G125-S142(G125-MAPALQPT-QGAMPAFA-S142),然后糖基化,其中氨基酸位置51处的甘氨酸被天冬酰胺取代,氨基酸位置94处的甘氨酸被氨基酸的天冬酰胺,苏氨酸和甘氨酸取代 位置133和135分别被天冬酰胺和丝氨酸取代,或者它们都被修饰。